Connection

FASIHA KANWAL to Retrospective Studies

This is a "connection" page, showing publications FASIHA KANWAL has written about Retrospective Studies.
Connection Strength

1.497
  1. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.049
  2. Cost of Care for Patients With Cirrhosis. Am J Gastroenterol. 2024 03 01; 119(3):497-504.
    View in: PubMed
    Score: 0.045
  3. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.043
  4. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.042
  5. Risk of Hepatocellular Carcinoma in Patients with Various HFE Genotypes. Dig Dis Sci. 2023 01; 68(1):312-322.
    View in: PubMed
    Score: 0.041
  6. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.041
  7. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
    View in: PubMed
    Score: 0.040
  8. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022 06; 75(6):1420-1428.
    View in: PubMed
    Score: 0.040
  9. Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. Hepatology. 2021 12; 74(6):3316-3329.
    View in: PubMed
    Score: 0.039
  10. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.039
  11. Elevated serum sodium in recipients of liver transplantation has a substantial impact on outcomes. Transpl Int. 2021 Oct; 34(10):1971-1983.
    View in: PubMed
    Score: 0.039
  12. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Intern Med. 2021 07 01; 181(7):949-959.
    View in: PubMed
    Score: 0.039
  13. Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure". J Hepatol. 2021 02; 74(2):477.
    View in: PubMed
    Score: 0.037
  14. Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Netw Open. 2020 11 02; 3(11):e2023780.
    View in: PubMed
    Score: 0.037
  15. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.037
  16. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 03; 71(3):808-819.
    View in: PubMed
    Score: 0.035
  17. Renal Trajectory Patterns Are Associated With Postdischarge Mortality in Patients With Cirrhosis and Acute Kidney Injury. Clin Gastroenterol Hepatol. 2020 07; 18(8):1858-1866.e6.
    View in: PubMed
    Score: 0.035
  18. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
    View in: PubMed
    Score: 0.034
  19. Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Dig Dis Sci. 2019 06; 64(6):1470-1477.
    View in: PubMed
    Score: 0.033
  20. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.032
  21. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018 11; 25(11):1270-1279.
    View in: PubMed
    Score: 0.031
  22. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
    View in: PubMed
    Score: 0.030
  23. Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2018 02; 16(2):252-259.
    View in: PubMed
    Score: 0.030
  24. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.029
  25. The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. Dig Dis Sci. 2017 May; 62(5):1180-1185.
    View in: PubMed
    Score: 0.029
  26. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
    View in: PubMed
    Score: 0.028
  27. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016 08; 64(2):569-81.
    View in: PubMed
    Score: 0.027
  28. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat. 2016 09; 23(9):687-96.
    View in: PubMed
    Score: 0.027
  29. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014 Dec; 60(6):1871-8.
    View in: PubMed
    Score: 0.024
  30. The quality of care provided to patients with varices in the department of Veterans Affairs. Am J Gastroenterol. 2014 Jul; 109(7):934-40.
    View in: PubMed
    Score: 0.024
  31. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul; 60(1):98-105.
    View in: PubMed
    Score: 0.024
  32. Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection. Dig Dis Sci. 2014 Feb; 59(2):273-81.
    View in: PubMed
    Score: 0.022
  33. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1270-1277.e3.
    View in: PubMed
    Score: 0.021
  34. The performance of process measures in hepatitis C. Am J Gastroenterol. 2012 Oct; 107(10):1512-21.
    View in: PubMed
    Score: 0.021
  35. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med. 2010 Aug 17; 153(4):231-9.
    View in: PubMed
    Score: 0.018
  36. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology. 2007 Dec; 46(6):1741-9.
    View in: PubMed
    Score: 0.015
  37. Natural History of Indeterminate Liver Nodules in Patients With Advanced Liver Disease: A Multicenter Retrospective Cohort Study. Am J Gastroenterol. 2024 Nov 01; 119(11):2251-2258.
    View in: PubMed
    Score: 0.012
  38. Hepatocellular Carcinoma Screening in a Contemporary Cohort of At-Risk Patients. JAMA Netw Open. 2024 Apr 01; 7(4):e248755.
    View in: PubMed
    Score: 0.012
  39. Emergency Presentations Predict Worse Outcomes Among Patients with Pancreatic Cancer. Dig Dis Sci. 2024 Feb; 69(2):603-614.
    View in: PubMed
    Score: 0.011
  40. A model to predict the development of mental status changes of unclear cause after liver transplantation. Liver Transpl. 2003 Dec; 9(12):1312-9.
    View in: PubMed
    Score: 0.011
  41. Radiological-histopathological discordance in patients transplanted for HCC and its impact on post-transplant outcomes. Cancer Med. 2023 07; 12(14):15011-15025.
    View in: PubMed
    Score: 0.011
  42. The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure. J Hepatol. 2023 09; 79(3):717-727.
    View in: PubMed
    Score: 0.011
  43. Survival following liver transplantation for hepatocellular carcinoma after implementation of MMaT-3 policy. Liver Transpl. 2023 10 01; 29(10):1138-1142.
    View in: PubMed
    Score: 0.011
  44. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clin Infect Dis. 2023 02 18; 76(4):592-599.
    View in: PubMed
    Score: 0.011
  45. Telehealth interventions in patients with chronic liver diseases: A systematic review. Hepatology. 2023 07 01; 78(1):179-194.
    View in: PubMed
    Score: 0.011
  46. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. Clin Gastroenterol Hepatol. 2023 08; 21(9):2288-2297.e4.
    View in: PubMed
    Score: 0.011
  47. Is Liver Transplant Justified at Any MELD Score? Transplantation. 2023 03 01; 107(3):680-692.
    View in: PubMed
    Score: 0.011
  48. Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review. Liver Transpl. 2022 12; 28(12):1865-1875.
    View in: PubMed
    Score: 0.010
  49. Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. Liver Transpl. 2023 01 01; 29(1):15-25.
    View in: PubMed
    Score: 0.010
  50. Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort. JAMA Netw Open. 2022 07 01; 5(7):e2223504.
    View in: PubMed
    Score: 0.010
  51. Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. Clin Transplant. 2022 06; 36(6):e14646.
    View in: PubMed
    Score: 0.010
  52. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clin Gastroenterol Hepatol. 2023 04; 21(4):1111-1113.e3.
    View in: PubMed
    Score: 0.010
  53. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2023 02; 21(2):415-423.e4.
    View in: PubMed
    Score: 0.010
  54. Marginal allografts in liver transplantation have a limited impact on length of stay. Clin Transplant. 2022 03; 36(3):e14544.
    View in: PubMed
    Score: 0.010
  55. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemp Clin Trials. 2021 05; 104:106367.
    View in: PubMed
    Score: 0.009
  56. Early Impact of COVID-19 on Solid Organ Transplantation in the United States. Transplantation. 2020 11; 104(11):2221-2224.
    View in: PubMed
    Score: 0.009
  57. Aggressive utilization of liver allografts: Improved outcomes over time. Clin Transplant. 2020 07; 34(7):e13860.
    View in: PubMed
    Score: 0.009
  58. Retrospective analysis of long-term outcome 10 years after liver transplantation for Wilson disease: experience over three decades. Transpl Int. 2020 08; 33(8):925-935.
    View in: PubMed
    Score: 0.009
  59. A learning curve in using orphan liver allografts for transplantation. Clin Transplant. 2020 04; 34(4):e13821.
    View in: PubMed
    Score: 0.009
  60. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020 02; 174:104698.
    View in: PubMed
    Score: 0.009
  61. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019 06; 49(11):1442-1447.
    View in: PubMed
    Score: 0.008
  62. Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. Dig Dis Sci. 2018 05; 63(5):1173-1181.
    View in: PubMed
    Score: 0.008
  63. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol. 2016 12; 65(6):1148-1154.
    View in: PubMed
    Score: 0.007
  64. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016 07; 64(1):130-7.
    View in: PubMed
    Score: 0.007
  65. New diagnosis of chronic pancreatitis: risk of missing an underlying pancreatic cancer. Am J Gastroenterol. 2014 Nov; 109(11):1824-30.
    View in: PubMed
    Score: 0.006
  66. Increased risk of pancreatic adenocarcinoma after acute pancreatitis. Clin Gastroenterol Hepatol. 2014 Jul; 12(7):1143-1150.e1.
    View in: PubMed
    Score: 0.006
  67. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013 May; 57(5):1858-68.
    View in: PubMed
    Score: 0.005
  68. National patterns and predictors of liver biopsy use for management of hepatitis C. J Hepatol. 2012 Aug; 57(2):252-9.
    View in: PubMed
    Score: 0.005
  69. Impact of nasogastric lavage on outcomes in acute GI bleeding. Gastrointest Endosc. 2011 Nov; 74(5):971-80.
    View in: PubMed
    Score: 0.005
  70. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011 Jan 18; 154(2):85-93.
    View in: PubMed
    Score: 0.005
  71. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011 Mar; 106(3):483-91.
    View in: PubMed
    Score: 0.005
  72. Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre. Aliment Pharmacol Ther. 2008 Nov 01; 28(9):1078-87.
    View in: PubMed
    Score: 0.004
  73. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant. 2005 Oct; 5(10):2433-40.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.